Moreover, a selective HTR2A antagonist showed efficacy in improving hepatic steatosis as predicted by Tph1 GKO mice and Htr2a LKO mice phenotypes in HFD-induced hepatic steatosis. The gene discussed is HTR2A; the disease is Hepatic steatosis.